Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma.

Abstract

OPINION STATEMENT:

Recently introduced systemic therapies for locally advanced and metastatic non-melanoma skin cancers (NMSCs) are paving the way for neoadjuvant approach. Although none of the therapeutic options has currently gained indication in this setting, neoadjuvant approach for NMSCs is an open field and we are likely to see huge developments in the near future. Targeted therapy with sonic hedgehog pathway inhibitors is very effective in locally advanced or multiple basal cell carcinomas while immunotherapy with immune checkpoint inhibitors appears to be promising for advanced cutaneous squamous cell carcinoma and Merkel cell carcinoma. To date, targeted therapy and immunotherapy represent the frontiers in NMSC therapeutic management and, according to recent studies, good results can be achieved.

• Authors: Enrico Zelin, Iris Zalaudek, Marina Agozzino, Caterina Dianzani, Arianna Dri, Nicola Di Meo, Roberta Giuffrida, Giovanni Francesco Marangi, Nicoleta Neagu, Paolo Persichetti, Ludovica Toffoli, Claudio Conforti
• Journal: Current treatment options in oncology (Curr Treat Options Oncol) Vol. 22 Issue 4 Pg. 35 (03 16 2021) ISSN: 1534-6277 [Electronic] United States
• PMID: 33725197 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Biomarkers, Tumor

Topics

• Biomarkers, Tumor
• Clinical Decision-Making
• Combined Modality Therapy (adverse effects, methods)
• Cost-Benefit Analysis
• Diagnosis, Differential
• Disease Management
• Disease Susceptibility
• Health Care Costs
• Humans
• Prognosis
• Skin Neoplasms (diagnosis, etiology, therapy)
• Treatment Outcome